Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
A new study aimed to confirm the possible synergy between loncastuximab and rituximab.
A phase 2 study presented at ASH 2024 hint at a chemo-free option for elderly patients with MCL
Treatment choice significantly influences outcomes in patients with mantle cell lymphoma.
Patients with follicular lymphoma and early progression are a distinctly vulnerable population who need further study.
Odronextamab showed durable response rates and an acceptable safety profile in the phase I ELM-1 and phase II ELM-2 trials.
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
Intravenous mosunetuzumab was administered in 21-day cycles, with step-up dosing integrated in cycle one.
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Swetha Kambhampati, MDAssistant Professor, Division of Lymphoma | City of Hope Comprehensive Cancer Center
Advertisement
Latest News
Section Editor
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.